Dance Biopharm to Present Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting

– This trial, conducted in patients with type 2 diabetes, compared
three doses each of Dance 501 inhaled insulin and subcutaneous insulin
lispro –

SAN FRANCISCO–(BUSINESS WIRE)–Dance
Biopharm Holdings, Inc., a privately-held clinical stage biopharma
company focused on the development of novel soft mist inhalable
formulations of biologics for people living with chronic diseases, today
announced presentations of Phase 2 clinical trial results for its
inhaled preservative-free human insulin, Dance 501, for the treatment of
diabetes. The data will be presented at the 79th
Scientific Sessions of the American Diabetes Association (#ADA2019),
which will be held June 7-11, 2019 at the Moscone Center in San
Francisco.

Details of the poster presentations are as follows:

Title: Dance 501 Inhaled Human Insulin (INH): Linear Dose
Response, Earlier Onset of Action, and Higher Early Effect than s.c.
Insulin Lispro (LIS)
Abstract: Control
#2019-A-5548-Diabetes
Poster Board: 1085-P in category 12-E
Clinical Therapeutics/New Technology–Insulins
Presenter:
Eric Zijlstra, Ph.D.
Presentation Details:
Session
Type: General Poster Session
Session Title: Saturday General
Poster Session
Session Date/Time: Saturday June 8, 2019 11:30 a.m.
– 12:30 p.m. PT
Location: Poster Hall (Hall F, North, Exhibition
Level)

Session Type: ePoster Theater
Session Title: Newest Insulins
Session
Date/Time: Sunday June 9, 2019 12:00 p.m. – 1:00 p.m. PT
Location: Exhibit
Hall (ePoster Theater B)

About Dance Biopharm

Dance Biopharm is a private company focused on developing novel inhaled
formulations of biologics to treat severe and chronic diseases. The
company’s novel inhalation delivery technology platform may be utilized
with liquid formulations of biologics with the goal of providing
effective and convenient treatment options to patients along with
wireless connectivity to improve disease management. Dance,
headquartered in the San Francisco Bay Area, was founded by John Patton,
Ph.D., who has over 25 years of experience developing numerous inhaled
therapies. For more information, please visit http://dancebiopharm.com.

FORWARD-LOOKING STATEMENTS

All statements other than statements of historical fact included in this
press release are forward-looking statements that are subject to certain
risks, trends and uncertainties that could cause actual results and
achievements to differ materially from those expressed in such
statements. We have based these forward-looking statements upon
information available to management of Dance as of the date of this
release and management’s expectations and projections about certain
future events. It is possible that the assumptions made by management
for purposes of such statements may not materialize. Actual results may
differ materially from those projected or implied in any forward-looking
statements. Such statements may involve risks and uncertainties,
including but not limited to those relating to our limited operating
history, our ability to successfully develop product candidates,
including Dance 501, the cost and uncertainty of obtaining regulatory
approvals, our ability to bring product candidates, including Dance 501,
to multiple markets and our ability to develop inhaled formulations of
other medicines.

Contacts

Investors
Robert H. Uhl
Managing Director
Westwicke IR
858-356-5932
[email protected]

Media
Jim Heins
Senior Vice President
Westwicke PR
203-682-8251
[email protected]